Search

Displaying results 5261 - 5270 of 10000 in total
  1. Drug

    Gantacurium

    go.drugbank.com/drugs/DB05710
    Investigational

    It is being developed by Avera Pharmaceuticals.

  2. Drug

    LP-2307

    go.drugbank.com/drugs/DB17470
    Experimental

    LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.

  3. Drug

    Florilglutamic acid F-18

    go.drugbank.com/drugs/DB15041
    Investigational

    Florilglutamic acid F-18 is under investigation in clinical trial NCT02370563 (PET Imaging of Intracranial Cancers With 18F-FSPG).

  4. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. … mutations in the kinase domain of FGFR.

  5. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    It is being developed by Exelixis, Inc. … XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation.

  6. Drug

    THR-184

    go.drugbank.com/drugs/DB19097
    Investigational

    THR-184 is under investigation in clinical trial NCT01830920 (A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-acute Kidney Injury (CSA-AKI)).

  7. Drug

    BRD-810

    go.drugbank.com/drugs/DB23607
    Experimental

    BRD-810 is an experimental small molecule being investigated as a potential anti-cancer medication. It is an inhibitor of the protein myeloid cell leukemia 1 (MCL1). [A274263]

  8. Drug

    Methoxy arachidonyl fluorophosphonate

    go.drugbank.com/drugs/DB02465
    Experimental

    It inhibits phospholipase A2 and fatty acid amide hydrolase with special potency, displaying IC50 values in the low-nanomolar range. … Methoxy arachidonyl fluorophosphonate, commonly referred as MAFP, is an irreversible active site-directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases.

  9. Drug

    VX-702

    go.drugbank.com/drugs/DB05470
    Investigational

    It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.

  10. Drug

    Iodopropynyl butylcarbamate

    go.drugbank.com/drugs/DB15666
    Investigational

    Synonyms: 3-iodo-2-propyn-1-yl N-butylcarbamate, 3-iodoprop-2-yn-1-yl butylcarbamateMixtures: Antibacterial Wet Wipes, Antibacterial Wet Wipes